Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 30;20(17):1151–1164. doi: 10.2217/fon-2022-1315

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 4. — Second-line treatment patterns according to sensitivity to platinum chemotherapy*.

Second-line treatment regimens used for patients with (A) platinum-sensitive and (B) platinum-resistant ES-SCLC between 2018 and 2021 in EU5.

*Regimens that collectively contributed <2% to total percentage from 2018 to 2021 are not shown. Consequently, percentages may not add up to 100%.

Carb: Carboplatin; Cyc/Dox/Vinc: Cyclophosphamide/doxorubicin/vincristine; Etop: Etoposide; ES-SCLC: Extensive-stage small-cell lung cancer; EU5: France, Germany, Italy, Spain and the UK.